U01HL156943

Sickle Hemoglobinopathy Research in Zimbabwe (SHAZ) - Abstract/Summary

The goal of the Sickle Hemoglobinopathy Research in Zimbabwe (SHAZ) application is to establish a sustainable infrastructure and operation aimed at addressing the limited data and gaps in Sickle Cell Disease (SCD) management that currently exists in Zimbabwe and Zambia. By contributing to the SCD in Sub-Saharan Africa (SSA) Network Consortium Registry and Biorepository, SHAZ aims to create accomplished SCD clinicians and research personnel who will focus on introduction and implementation of the SCD in SSA Network Registry efforts.

Enrolling at least 4,000 individuals with SCD from Zambia and Zimbabwe over a five-year period, the SHAZ team will aim to integrate regional SCD evidence-based management guidelines. They will also develop three cohort studies to generate more evidence on heritability of clinical phenotype of SCD, describing the natural history and clinical correlates of adverse outcomes in SCD patients. Specifically, they will explore the association between abnormal cerebral blood flow and foetal hemoglobin level as a risk factor for stroke.

Furthermore, implementation science research will be utilized as a tool to promote uptake of the evidence-based practices that improve outcomes in SCD patients, namely: newborn screening, improved nutrition, and hydroxyurea use in the two countries.

Faculty Of Medicine And Health Sciences University Of Zimbabwe

THE DIVISION OF BLOOD DISEASES AND RESOURCES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE PATHOPHYSIOLOGY, DIAGNOSIS, TREATMENT, AND PREVENTION OF NON-MALIGNANT BLOOD DISEASES, INCLUDING ANEMIAS, SICKLE CELL DISEASE, THALASSEMIA, LEUKOCYTE BIOLOGY, PRE-MALIGNANT PROCESSES SUCH AS MYELODYSPLASIA AND MYELOPROLIFERATIVE DISORDERS, HEMOPHILIA AND OTHER ABNORMALITIES OF HEMOSTASIS AND THROMBOSIS, AND IMMUNE DYSFUNCTION. FUNDING ENCOMPASSES A BROAD SPECTRUM OF HEMATOLOGIC INQUIRY, RANGING FROM STEM CELL BIOLOGY TO MEDICAL MANAGEMENT OF BLOOD DISEASES AND TO ASSURING THE ADEQUACY AND SAFETY OF THE NATION'S BLOOD SUPPLY. PROGRAMS ALSO SUPPORT THE DEVELOPMENT OF NOVEL CELL-BASED THERAPIES TO BRING THE EXPERTISE OF TRANSFUSION MEDICINE AND STEM CELL TECHNOLOGY TO THE REPAIR AND REGENERATION OF HUMAN TISSUES AND ORGANS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.

93.837 - Cardiovascular Diseases Research

National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]

Zimbabwe

Foreign

Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional) (RFA-HL-21-009)

Amendment Since initial award the total obligations have increased 737% from $108,000 to $904,461.